A stock offering by Trius Therapeutics is bringing in $34.1 million to fund research and development and other corporate expenses. Tedizolid phosphate, the firm's lead product, is being tested against severe infections such as methicillin-resistant Staphylococcus aureus.
Antibiotic company Trius secures funding for R&D
SmartBrief Job Listings for Health Care
|Sr. Regulatory Specialist, Biotech Center of Expertise||
BASF, The Chemical Co.
|San Diego, CA|
|Director of Clinical Research||
Regenesis Biomedical, Inc.
Meridian Health Plan
|Assistant Vice President - Dental Director||